237 related articles for article (PubMed ID: 36119029)
1. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
Front Immunol; 2022; 13():982346. PubMed ID: 36119029
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
[TBL] [Abstract][Full Text] [Related]
6. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
7. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
[TBL] [Abstract][Full Text] [Related]
8. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.
Lan TY; Lin YC; Tseng TC; Yang HC; Kao JH; Cheng CF; Lee TJ; Huang SC; Lu CH; Li KJ; Hsieh SC
Gut Liver; 2023 Mar; 17(2):288-298. PubMed ID: 36268584
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.
Chiu CY; Ahmed S; Thomas SK; Wang LS; Mustafayev K; Fayad LE; Wierda WG; Khawaja F; Torres HA
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):610-615. PubMed ID: 37150651
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP.
Zhan Z; Guo W; Wan X; Wang B; Li J; Wang H; Li Z; Huang Y; Young KH; Bai O
Front Immunol; 2024; 15():1324113. PubMed ID: 38318173
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
13. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.
Guo YF; Pan JX; Zhuang WH
Infect Agent Cancer; 2018; 13():40. PubMed ID: 30559832
[TBL] [Abstract][Full Text] [Related]
14. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
16. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
Huang HH; Hsiao FY; Chen HM; Wang CY; Ko BS
Br J Haematol; 2021 Jan; 192(1):110-118. PubMed ID: 33131074
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy.
Visentini M; Pica A; D'Ippolito G; Sculco E; La Gualana F; Gragnani L; Miglionico M; Mazzaro C; Fiorilli M; Basili S; Martelli M; Di Rocco A; Casato M; Gentile G; Pulsoni A
Ann Hematol; 2023 Dec; 102(12):3457-3463. PubMed ID: 37650886
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
19. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.
Zeng Y; Huang J; Pang J; Pan S; Wu Y; Jie Y; Li X; Chong Y
Front Immunol; 2024; 15():1330644. PubMed ID: 38558804
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]